Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer

1 Jan 2021

Abstract excerpt

These results suggest that activation of the LPL/FABP4/CPT1 axis is essential for LCSCs maintenance, which acts synergistically with a variety of up-regulated oncogenic signals that drive the hepatocyte-LCSCs transdifferentiation during NASH to HCC progression. Thus, targeting the LPL/FABP4/CPT1 axis may provide a potential direction for NASH-related HCC prevention.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Liver Disease Diagnosis and Treatment
Share to Peroxisome Proliferator-Activated Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34803493
DOI: 10.7150/ijbs.64714

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancerPMID 34803493Read ↗

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular CarcinomaSemantic proximity Read ↗

Specific unsaturated fatty acids enforce the transdifferentiation of human cancer cells toward adipocyte-like cells.Semantic proximity Read ↗

Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implicationsSemantic proximity Read ↗

Regulation of fatty acid oxidation by liraglutide via SIRT1 in hepatocytes: A mechanistic studySemantic proximity Read ↗

SREBP Regulation of Lipid Metabolism in Liver Disease, and Therapeutic StrategiesSemantic proximity Read ↗

LncNONMMUG027912 alleviates lipid accumulation through AMPKα/mTOR/SREBP1C axis in nonalcoholic fatty liverSemantic proximity Read ↗

The Role of TM6SF2 in Non-Alcoholic Fatty Liver Disease: From Mechanisms To Therapeutic StrategySemantic proximity Read ↗

Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A reviewSemantic proximity Read ↗

Single-cell transcriptome reveals a novel mechanism of C-Kit+-liver sinusoidal endothelial cells in NASHSemantic proximity Read ↗

Identification of Downregulated Exosome-Associated Gene ENPP1 as a Novel Lipid Metabolism and Immune-Associated Biomarker for Hepatocellular CarcinomaSemantic proximity Read ↗

Role of Long Chain Acyl-CoA Synthetases in MASH-driven Hepatocellular Carcinoma and FerroptosisSemantic proximity Read ↗

Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.